Tolerance is the key to understanding antimalarial drug resistance

Trends in Parasitology

Volumn 22, Issue 2, 2006, Pages 71-77

  Hastings, Ian M ^a   Watkins, William M ^b  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTESUNATE; ARTESUNATE PLUS FANSIDAR; CHLORPROGUANIL PLUS DAPSONE; FANSIDAR; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; COMBINATION CHEMOTHERAPY; DISEASE TRANSMISSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SENSITIVITY; DRUG TOLERANCE; EVOLUTIONARY ADAPTATION; GEOGRAPHIC DISTRIBUTION; HUMAN; MALARIA; NONHUMAN; REINFECTION; REVIEW;

ARTESUNATE;

EID: 31344466681     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2005.12.011     Document Type: Article

References (47)

1. C.F. Curtis, and L.N. Otoo A simple model of the build-up of resistance to mixtures of anti-malarial drugs Trans. R. Soc. Trop. Med. Hyg. 80 1986 889 892
2. C. Dye, and B.G. Williams Multigenic drug resistance among inbred malaria parasites Proc. Biol. Sci. 264 1997 61 67
3. I.M. Hastings A model for the origins and spread of drug-resistant malaria Parasitology 115 1997 133 141
4. I.M. Hastings, and U. D'Alessandro Modelling a predictable disaster: the rise and spread of drug-resistant malaria Parasitol. Today 16 2000 340 347
5. I.M. Hastings The evolution of drug-resistant malaria; the role of drug elimination half-life Philos. Trans. R. Soc. Lond. B. Biol. Sci. 357 2002 505 519
6. C.H. Sibley Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol. 17 2001 582 588
7. W.M. Watkins, and M. Mosobo Treatment of Plasmodium falciparum malaria with pyrimethamine-sulphadoxine: selective pressure for resistance is a function of long half-life Trans. R. Soc. Trop. Med. Hyg. 87 1993 75 78
8. I.M. Hastings, and W.M. Watkins Intensity of malaria transmission and the evolution of drug resistance Acta Trop. 94 2005 218 229
9. A. Nzila Why has the dihydrofolate reductase 164 mutation not consistently been found in Africa yet? Trans. R. Soc. Trop. Med. Hyg. 99 2005 341 346
10. A.M. Nzila Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum J. Infect. Dis. 181 2000 2023 2028
11. C. Sisowath In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by Artemether-Lumefantrine (Coartem) J. Infect. Dis. 191 2005 1014 1017
12. I.M. Hastings, and S.A. Ward Coartem in Africa - the beginning of the end? J. Infect. Dis. 192 2005 1303 1304
13. J. Sulo Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial Lancet 360 2002 1136 1143
14. R.W. Snow Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa Trends Parasitol. 19 2003 363 369
15. B. Greenwood Why do some African children develop severe malaria? Parasitol. Today 7 1991 277 281
16. J.F. Cortese Origin and dissemination of Plasmodium falciparum drug-resistance mutations in South America J. Infect. Dis. 186 2002 999 1006
17. T.J.C. Anderson, and C. Roper The origins and spread of antimalarial drug resistance: lessons for policy makers Acta Trop. 94 2005 269 280
18. S. Nair A selective sweep driven by pyrimethamine treatment in SE Asian malaria parasites Mol. Biol. Evol. 20 2003 1526 1536
19. C. Roper Intercontinental spread of pyrimethamine-resistant malaria Science 305 2004 1124
20. J.C. Wootton Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum Nature 418 2002 320 323
21. R.A. Fisher The wave of advance of advantageous genes Ann. Eugen. 7 1937 355 369
22. C.L. Morjan, and L.H. Rieseberg How species evolve collectively: implications of gene flow and selection for the spread of advantageous alleles Mol. Ecol. 13 2004 1341 1356
23. M. Slatkin The rate of spread of an advantageous allele in a subdivided population S. Karlin E. Nevo Population Genetics and Ecology 1976 Academic Press 767 780
24. M. Slatkin, and D. Charlesworth The spatial distribution of transient alleles in a subdivided population: a simulation study Genetics 89 1978 793 810
25. N.J. White Preventing antimalarial drug resistance through combinations Drug Res. Updates 1 1998 3 9
26. N.J. White, and P.L. Olliaro Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria Parasitol. Today 12 1996 399 401
27. N.J. White Antimalarial drug resistance and combination chemotherapy Phil. Trans. R. Soc. London Ser. B. 354 1999 739 749
28. World Health Organization Antimalarial Drug Combination Therapy. Report of a Technical Consultation 2001 World Health Organization
29. W. Peters Chemotherapy and Drug Resistance in Malaria 1987 Academic Press
30. R.N. Price, and F. Nosten Drug resistant falciparum malaria: clinical consequences and strategies for prevention Drug Res. Updates 4 2001 187 196
31. N.J. White, and W. Pongtavornpinyo The de novo selection of drug-resistant malaria parasites Proc. R. Soc. Lond. B. Biol. Sci. 270 2003 545 554
32. I.M. Hastings The origins of antimalarial drug resistance Trends Parasitol. 20 2004 512 518
33. A.O. Talisuna History, dynamics, and public health importance of malaria parasite resistance Clin. Microbiol. Rev. 17 2004 235 254
34. F. Abacassamo Efficacy of chloroquine, amodiaquine, sulphadoxine- pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria Trop. Med. Int. Health 9 2004 200 208
35. I. van den Broek Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years Malakal, Upper Nile, Sudan. Malar. J. 4 2005 14
36. E. Depoortere Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia Trop. Med. Int. Health 9 2004 62 67
37. G. Dorsey Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial Lancet 360 2002 2031 2038
38. W.M. Watkins The efficacy of antifolate antimalarial combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses Parasitol. Today 13 1997 459 464
39. W.M. Watkins The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: a model of the selection of resistance by antifolate drugs and their combinations Am. J. Trop. Med. Hyg. 72 2005 163 173
40. International Artemisinin Study Group Artesunate combinations for treatment of malaria: meta-analysis Lancet 363 2004 9 17
41. A.P. Alker Mutations associated with sulfadoxine-pyrimethamine and chlorproguanil resistance in Plasmodium falciparum isolates from Blantyre, Malawi Antimicrob. Agents Chemother. 49 2005 3919 3921
42. C. Roper Antifolate antimalarial resistance in southeast Africa: a population-based analysis Lancet 361 2003 1174 1181
43. W. Sirawaraporn Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase Proc. Natl. Acad. Sci. U. S. A. 94 1997 1124 1129
44. J.T. Ferlan Mutagenesis of dihydrofolate reductase from Plasmodium falciparum: analysis in Saccharomyces cerevisiae of triple mutant alleles resistant to pyrimethamine or WR99210 Mol. Biochem. Parasitol. 113 2001 139 150
45. E.G. Hankins Novel alleles of the Plasmodium falciparum dhfr highly resistant to pyrimethamine and chlorcycloguanil, but not WR99210 Mol. Biochem. Parasitol. 117 2001 91 102
46. L.K. Basco Molecular epidemiology of malaria in Cameroon. XVI. Longitudinal surveillance of in vitro pyrimethamine resistance in Plasmodium falciparum Am. J. Trop. Med. Hyg. 69 2003 174 178
47. A. Nzila-Mounda Kenyan Plasmodium falciparum field isolates: correlation between pyrimethamine and chlorcycloguanil activity in vitro and point mutations in the dihydrofolate reductase domain Antimicrob. Agents Chemother. 42 1998 164 169